0

Vaccines Market by Type and Geography - Forecast and Analysis 2022-2026

  • Published: Apr 2022
  • Pages: 136
  • SKU: IRTNTR40041
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

According to Technavio's analyst, the vaccines market size is expected to be valued at USD 28.28 billion by 2026 with a progressing CAGR of 4.13%.

This vaccines market research report extensively covers vaccines market segmentation by the following:

  • Type - Prophylactic vaccines and Therapeutic vaccines
  • Geography - North America, Europe, Asia, and Rest of World (ROW)

The vaccines market vendors are - Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE among others.

What will the Vaccines Market Size be During the Forecast Period?

Vaccines Market Size

Download the Free Report Sample to Unlock the Vaccines Market Size for the Forecast Period and Other Important Statistics

 

Vaccines Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post-COVID-19 era. The increased funding for vaccine development and new vaccine launches is notably driving the vaccines market growth, although factors such as high cost of vaccine research, development, and manufacturing may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the vaccines industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Vaccines Market Driver

One of the key factors driving growth in the vaccines market is the increased funding for vaccine development and new vaccine launches. Over the past years, there have been variations in the health of the global population, primarily due to improved public health measures, the application of science-based medicine, and the emergence of vaccines for serious infectious diseases. The research and development of vaccines have led to the eradication of several serious infectious diseases. However, to understand the life cycle management and stringent timelines for vaccine development, manufacturers need to invest heavily in their technical capabilities. Therefore, it has become essential for manufacturers, regulators, and suppliers to work collectively to understand the challenges and opportunities for the development of vaccines. Several companies and organizations across the globe have increased their funding for the development and launch of new vaccines. The increase in investment and launch of vaccines to treat various infectious diseases will drive the growth of the market focus during the forecast period.

Key Vaccines Market Trend

The development of nanoparticle vaccines is a vaccines market trend that is expected to have a positive impact in the coming years. Various infectious and other diseases have emerged as a serious threat to the health of millions of people worldwide. Researchers across the globe are making efforts not only to develop new vaccines but also to improve the efficacy of current vaccines against specific diseases. Until now, some vaccines were developed from protein subunits and killed pathogens, whereas several vaccines were based on live attenuated organisms. These vaccines have the risk of regaining their pathogenicity under certain immunocompromised conditions. Therefore, to overcome this challenge, the development of effective vaccines in combination with adequate delivery systems is important to obtain the desired humoral and cell-mediated immunity against specific diseases. Due to several advantages of nanoparticle vaccines, the R&D of these vaccines has increased globally. The development of nanoparticle vaccines has helped in demonstrating effective immune potentiation by nano formulations, further offering improved vaccine safety, potency, and availability in the treatment of various diseases.

Key Vaccines Market Challenge

The high cost of vaccine research, development, and manufacturing will be a major challenge for the vaccines market during the forecast period. Vaccine development has played an important role in combating various infectious and life-threatening diseases, e.g., the successful eradication of smallpox in several countries. Despite this achievement, there is still a great need for new vaccines. However, these achievements are emerging slowly due to the requirement for high investment in developing and manufacturing vaccines. Owing to such a high cost of research, development, and manufacturing of vaccines, the price of vaccines for patients is set to be high. In addition, new vaccines are more complex to produce than older ones, which contributes to their higher cost. The high cost of vaccines has a negative impact on patient compliance and adherence to vaccines, which limits the growth of the market. Therefore, it has become important to develop vaccines with novel routes of administration coupled with low cost.

This vaccines market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global vaccines market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the vaccines market during the forecast period.

Who are the Major Vaccines Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bavarian Nordic AS
  • Bharat Biotech Ltd.
  • BrightPath Biotherapeutics Co. Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Gradalis Inc.
  • Inovio Pharmaceuticals Inc.
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Mitsubishi Chemical Holdings Corp.
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Valneva SE

 

This statistical study of the vaccines market encompasses successful business strategies deployed by the key vendors. The vaccines market is fragmented and the vendors are deploying growth strategies such as forming strategic alliances to increase their product offerings and geographical reach to compete in the market.

Product Insights and News

  • Astellas Pharma Inc. - Astellas Pharma Inc. is a public company headquartered in Japan. It is a global company generating $12,120.42 million in revenues and has around 15,455 employees. Its revenue from the global vaccines market contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. 
  • Astellas Pharma Inc. - The company offers vaccine namely MAPS vaccine targeted to prevent and reduce the spread of pneumococcal disease.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The vaccines market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Vaccines Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the vaccines market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Vaccines Market?

Vaccines Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

48% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for vaccines in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The increasing number of immunization programs and strong prevalence of infectious diseases such as influenza, hepatitis A, hepatitis B, HIV, measles, malaria, and tuberculosis, and non-infectious diseases such as cancer will facilitate the vaccines market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The vaccines market in North America witnessed strong growth in 2021, owing to the negative impact of the COVID-19 pandemic. However, the high demand for vaccines is likely to return to normalcy after 2021 due to the lack of an urgent need for vaccines in North America once the population is vaccinated against COVID-19.

What are the Revenue-generating Type Segments in the Vaccines Market?

Vaccines Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The vaccine market share growth in the prophylactic vaccines segment will be significant during the forecast period. There are different types of prophylactic vaccines, such as live attenuated vaccines, inactivated vaccines, recombinant vaccines, and toxoid vaccines. Researchers are encouraged to develop new approaches to overcome the limitations that are associated with the current live attenuated influenza vaccines. The advances in live attenuated vaccine development will drive the growth of the segments during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the vaccine market size and actionable market insights on the post-COVID-19 impact on each segment.

You may be interested in:

Vaccine Research market - The market share is expected to increase to USD 13.34 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.36%.

Meningococcal Vaccines market - The market share should rise by USD 1.68 billion from 2021 to 2025 at a CAGR of 8.94%. 

Hepatitis B Vaccines market - The market size will record an incremental growth of USD 524.00 million and a CAGR of over 4% during 2020-2024.

Therapeutic Vaccines market - The market size is expected to grow by $ 3.78 bn and record a CAGR of 43% during 2020-2024.

Vaccines Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 4.13%

Market growth 2022-2026

$ 28.28 billion

Market structure

Fragmented

YoY growth (%)

4.0

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 48%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Vaccines Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive vaccines market growth during the next five years
  • Precise estimation of the vaccines market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the vaccines industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of vaccines market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Type

    • 5.1 Market segments
      • Exhibit 24: Chart on Type - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
    • 5.2 Comparison by Type
      • Exhibit 26: Chart on Comparison by Type
      • Exhibit 27: Data Table on Comparison by Type
    • 5.3 Prophylactic vaccines - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Prophylactic vaccines - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 29: Data Table on Prophylactic vaccines - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 30: Chart on Prophylactic vaccines - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Prophylactic vaccines - Year-over-year growth 2021-2026 (%)
    • 5.4 Therapeutic vaccines - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Therapeutic vaccines - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 33: Data Table on Therapeutic vaccines - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 34: Chart on Therapeutic vaccines - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Therapeutic vaccines - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Type
      • Exhibit 36: Market opportunity by Type ($ billion)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 UK - Market size and forecast 2021-2026
      • Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.10 Canada - Market size and forecast 2021-2026
      • Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.11 France - Market size and forecast 2021-2026
      • Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ billion)
      • Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ billion)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 Astellas Pharma Inc.
              • Exhibit 85: Astellas Pharma Inc. - Overview
              • Exhibit 86: Astellas Pharma Inc. - Product / Service
              • Exhibit 87: Astellas Pharma Inc. - Key news
              • Exhibit 88: Astellas Pharma Inc. - Key offerings
            • 10.4 AstraZeneca Plc
              • Exhibit 89: AstraZeneca Plc - Overview
              • Exhibit 90: AstraZeneca Plc - Product / Service
              • Exhibit 91: AstraZeneca Plc - Key news
              • Exhibit 92: AstraZeneca Plc - Key offerings
            • 10.5 Bavarian Nordic AS
              • Exhibit 93: Bavarian Nordic AS - Overview
              • Exhibit 94: Bavarian Nordic AS - Product / Service
              • Exhibit 95: Bavarian Nordic AS - Key news
              • Exhibit 96: Bavarian Nordic AS - Key offerings
            • 10.6 Bharat Biotech Ltd.
              • Exhibit 97: Bharat Biotech Ltd. - Overview
              • Exhibit 98: Bharat Biotech Ltd. - Product / Service
              • Exhibit 99: Bharat Biotech Ltd. - Key news
              • Exhibit 100: Bharat Biotech Ltd. - Key offerings
            • 10.7 BrightPath Biotherapeutics Co. Ltd.
              • Exhibit 101: BrightPath Biotherapeutics Co. Ltd. - Overview
              • Exhibit 102: BrightPath Biotherapeutics Co. Ltd. - Product / Service
              • Exhibit 103: BrightPath Biotherapeutics Co. Ltd. - Key offerings
            • 10.8 CSL Ltd.
              • Exhibit 104: CSL Ltd. - Overview
              • Exhibit 105: CSL Ltd. - Business segments
              • Exhibit 106: CSL Ltd. - Key news
              • Exhibit 107: CSL Ltd. - Key offerings
              • Exhibit 108: CSL Ltd. - Segment focus
            • 10.9 Daiichi Sankyo Co. Ltd.
              • Exhibit 109: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 110: Daiichi Sankyo Co. Ltd. - Business segments
              • Exhibit 111: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 112: Daiichi Sankyo Co. Ltd. - Key offerings
              • Exhibit 113: Daiichi Sankyo Co. Ltd. - Segment focus
            • 10.10 Emergent BioSolutions Inc.
              • Exhibit 114: Emergent BioSolutions Inc. - Overview
              • Exhibit 115: Emergent BioSolutions Inc. - Product / Service
              • Exhibit 116: Emergent BioSolutions Inc. - Key news
              • Exhibit 117: Emergent BioSolutions Inc. - Key offerings
            • 10.11 GlaxoSmithKline Plc
              • Exhibit 118: GlaxoSmithKline Plc - Overview
              • Exhibit 119: GlaxoSmithKline Plc - Business segments
              • Exhibit 120: GlaxoSmithKline Plc - Key news
              • Exhibit 121: GlaxoSmithKline Plc - Key offerings
              • Exhibit 122: GlaxoSmithKline Plc - Segment focus
            • 10.12 Gradalis Inc.
              • Exhibit 123: Gradalis Inc. - Overview
              • Exhibit 124: Gradalis Inc. - Product / Service
              • Exhibit 125: Gradalis Inc. - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 126: Inclusions checklist
                • Exhibit 127: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 128: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 129: Research methodology
                • Exhibit 130: Validation techniques employed for market sizing
                • Exhibit 131: Information sources
              • 11.5 List of abbreviations
                • Exhibit 132: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Vaccines market growth will increase by $28.28 billion during 2022-2026.
              The vaccines market is expected to grow at a CAGR of 4.13% during 2022-2026.
              Technavio has segmented the vaccines market by type (Prophylactic vaccines and Therapeutic vaccines) and geographic (North America, Europe, Asia, and Rest of World (ROW)).
              Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., Valneva SE are a few of the key vendors in the vaccines market.
              North America will register the highest growth rate of 48.13% among the other regions. Therefore, the vaccines market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              • US
              • Canada
              • Germany
              • UK
              • France
              The key factors driving the vaccines market growth are:
              • Increased funding for vaccine development and new vaccine launches
              • Development of nanoparticle vaccines
              The vaccines market vendors should focus on grabbing business opportunities from the prophylactic vaccines segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>